The new Vascepa program, marketed by Amarin Pharmaceuticals, offers a prescription fish-oil-derived medication designed to lower triglycerides in the blood [1]. To determine how this program might benefit you, consider the following key points:

The Vascepa program has been shown to significantly reduce triglyceride levels, a major risk factor for heart disease [2]. In clinical trials, patients taking Vascepa experienced substantial reductions in triglyceride levels, which may help prevent cardiovascular events such as heart attacks and strokes.

According to Amarin's data, patients on Vascepa have demonstrated a significant reduction in major adverse cardiovascular events (MACE), which includes heart attacks, strokes, and deaths from cardiovascular causes [3].

Moreover, the Vascepa program has undergone extensive clinical testing to ensure its safety and efficacy. The medication, also known as icosapent ethyl, has been found to be relatively well-tolerated, with side effects typically mild and rare [4].

If you are at risk for heart disease or have high triglycerides, you may benefit from the new Vascepa program. However, it is essential to consult with your healthcare provider to discuss your individual needs and determine if Vascepa is right for you.

Sources:

1. DrugPatentWatch.com - Information on icosapent ethyl (Vascepa)
2. ClinicalTrials.gov - VA-22967 Study results demonstrating Vascepa's efficacy
3. Amarin Pharmaceuticals www.amarincorp.com - Company website discussing major adverse cardiovascular events (MACE)
4. MedlinePlus.gov - US National Library of Medicine Information on Vascepa